See Graham's ranking
4.0
Thermo Fisher Scientific Inc. is a United States–based company operating in the healthcare sector, within the biotechnology, laboratory-instrumentation and scientific-solutions industry.
The company specializes in developing analytical instruments, reagents, consumables, diagnostic platforms, laboratory equipment and research technologies used by scientific institutions, hospitals, universities, pharmaceutical companies and biotechnology firms worldwide.
The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International, combining complementary strengths in analytical instrumentation and laboratory distribution.
Thermo Fisher’s portfolio includes spectrometers, electron microscopes, genomic-sequencing systems, cell-culture technologies, PCR instruments, chemical-analysis platforms, bioprocessing solutions, clinical reagents, laboratory consumables and advanced molecular-diagnostics tools.
It also provides biopharmaceutical manufacturing services, scientific support, contract development and manufacturing services, and technologies supporting the discovery and production of complex therapies, including cell and gene therapies.
The company operates globally across more than 50 countries, with manufacturing facilities, research laboratories, technology-development centers, distribution networks, regulated pharmaceutical-production sites and specialized scientific-support teams.
Its operational structure integrates engineering, biotechnology, analytical sciences, global logistics and partnerships with academic institutions, government agencies and pharmaceutical manufacturers.
Market factors influencing Thermo Fisher include advances in biotechnology, growing demand for molecular diagnostics, expansion of genomic research, development of personalized therapies, investment in laboratory infrastructure, regulatory requirements, pharmaceutical innovation cycles and the increasing need for high-performance scientific technologies.
The company benefits from a diversified portfolio that spans nearly every stage of biomedical research and production.
Thermo Fisher Scientific Inc.’s shares are listed on the New York Stock Exchange (NYSE) under the ticker TMO.
History and when Thermo Fisher Scientific Inc. was founded
Thermo Fisher Scientific’s origins lie in two separate historical paths. Thermo Electron Corporation, founded in 1956, specialized in analytical instruments, engineering technologies and scientific solutions, growing through sustained innovation and targeted acquisitions in chemical analysis, diagnostics and laboratory instrumentation. Meanwhile, Fisher Scientific, founded in 1902, became a leading global supplier of laboratory reagents, consumables and equipment.
In 2006, Thermo Electron and Fisher Scientific merged to form Thermo Fisher Scientific Inc., creating one of the world’s largest scientific-technology companies. The merger unified analytical-instrumentation capabilities with extensive distribution networks and a broad consumables portfolio, establishing an integrated ecosystem serving the full continuum of scientific research and development.
Following the merger, the company expanded aggressively through acquisitions, notably Life Technologies in 2014, which significantly strengthened its genomic-sequencing and molecular-biology capabilities, and Patheon in 2017, which broadened its role in contract biopharmaceutical manufacturing. These moves positioned Thermo Fisher as a key partner for pharmaceutical development and clinical innovation.
Between 2020 and 2024, the company played a central role in supporting global molecular diagnostics and biomedical research. The period involved substantial investments in bioprocessing capacity, expansion of manufacturing sites, development of next-generation PCR and sequencing technologies, and enhanced support for pharmaceutical research and clinical testing. Thermo Fisher solidified its status as a global leader in scientific innovation and applied biotechnology.
Additional Information
The Company Thermo Fisher Scientific Inc. (United States), is listed on NYSE with a market value of $ 223.97 Billions, having an equity of $ 51.15 Billions.
With a total of 80.000 employees, the company is listed in the sector of Health and categorized in industry of Life Science Tools and Services.
In the last 12 months the Company had a revenue of $ 43.74 Billions, which generated a profit in the amount of $ 6.57 Billions.
As for its main indicators, the Company has a P/E ratio of 34.09, a P/BV ratio of 4.38 and in the last 12 months the dividend yield of TMO was at 0.28%.
The Company is traded internationally through the ticker TMO.
